ObsEva SA (OBSV) News Headlines

▮ More

Date

Headline

9/13/2022 1:59:19 AM ObsEva Axing 70% Of Employees To Cut Costs

9/13/2022 1:04:06 AM ObsEva Announces Progress On Restructuring Initiatives; Sees $7.6 Mln Annual Savings

8/27/2022 3:08:07 AM Biotech Stocks Facing FDA Decision In September

8/22/2022 1:04:51 AM ObsEva Receives Nasdaq Non-Compliance Notice

6/17/2022 1:33:46 AM ObsEva : European Commission Approves Yselty To Treat Uterine Fibroids

6/17/2022 1:04:36 AM ObsEva: EC Grants Marketing Authorization For Yselty For Treatment Of Uterine Fibroids

5/17/2022 1:06:11 AM ObsEva Q1 Net Loss $11.8 Mln Or $0.14/Shr Vs Loss $20.0 Mln Or $0.29/Shr Last Year

5/9/2022 1:06:18 AM ObsEva Presents Clinical Data On Oral GnRH Antagonist Linzagolix For Uterine Fibroids At The 2022 ACOG ACSM

5/2/2022 1:32:49 AM ObsEva Chief Clinical Officer Elizabeth Garner Quits; Brandi Named Replacement

5/2/2022 1:04:23 AM ObsEva Appoints Brandi Howard As Chief Clinical Officer, Effective May 9

4/25/2022 1:18:11 AM ObsEva: CHMP Of European Medicines Agency Confirms Positive Opinion For Linzagolix For Uterine Fibroids

3/22/2022 2:40:40 AM ObsEva Announces Addl Efficacy Results For Linzagolix On Endometriosis-associated Pain

3/22/2022 2:05:13 AM ObsEva Announces Addl Efficacy Results From Phase 3 EDELWEISS 3 Trial Of Linzagolix

2/1/2022 7:38:30 AM Pre-market Movers: KSCP, OBSV, SPIR, SI, CIAN…

2/1/2022 1:05:54 AM ObsEva Appoints Katja Buhrer As Chief Strategy Officer, Effective Feb. 1

1/31/2022 7:47:34 AM Pre-market Movers: FGI, IMPP, KSCP, WKEY, HAPP…

1/6/2022 7:34:31 AM Pre-market Movers: KAVL, ATHE, BLI, PSTV, CNSP…

1/6/2022 1:22:08 AM ObsEva: Linzagolix Phase 3 Trial Shows Positive Topline Results In Women With Moderate-to-severe EAP

1/6/2022 1:04:48 AM ObsEva Announces Positive Topline Results From Phase 3 EDELWEISS 3 Trial Of Linzagolix

12/17/2021 7:18:47 AM Pre-market Movers: GNFT, ABEO, SPRB, IO, CERN…

Obseva Sa (OBSV)